Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 21 recruiting now early-phase tilt

Malignant Neoplasm: early-phase trial registry

21 of 61 indexed Malignant Neoplasm trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #232 of 28,707 conditions by registered trial count.

61 US clinical trials · 21 currently recruiting · #232 of 28,707 conditions by registered trial count

Malignant Neoplasm: 61 US clinical trials tracked, 21 recruiting.

Malignant Neoplasm is the subject of 61 registered US clinical trials on ClinicalTrials.gov, 21 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 14 of these trials.

Enrollment posture brief

Registry condition malignant-neoplasm

OPEN 21 | RECR 34% | LATE 4 | EARLY 18 | RANK #232 | SPON 14

Nearest open-share peer: Chronic Lymphocytic Leukemia (34% recruiting · 189 trials)

Cholangiocarcinoma59%Cognitive Decline58.1%Depressive Symptoms45.9%Malignant Neoplasm (this)34%HIV/AIDS24.2%
Open-enrollment share among volume-matched conditions near Malignant Neoplasm

Malignant Neoplasm lists 21 open slots (34% of 61 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Malignant Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Malignant Neoplasm is recruiting below its size-band peers.

    21 of 61 indexed trials (34.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Malignant Neoplasm research.

    M.D. Anderson Cancer Center accounts for 14 of 61 trials (23%). 27 distinct sponsors appear on at least one study for this condition label.

  3. Typical Malignant Neoplasm enrolment sits around 118 participants.

    Median target enrolment is 118 among the 60 trials that report a genuine target (sentinel values excluded). 25 of those (41.7%) plan for fewer than 100 participants.

  4. Malignant Neoplasm research is mostly interventional.

    48 interventional and 13 observational studies make up this index (78.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 110Phase 28Phase 34

Open and recent trials

61 total, page 1 of 2

RECRUITING open-ended (no fixed target)

Molecular Genetics Studies of Cancer Patients and Their Relatives

City of Hope Medical Center

NCT04185935

RECRUITING 10,000 participants

Norris ORIEN Total Cancer Care

University of Southern California

NCT02970045

RECRUITING 6,500 participants

New Assessment System in Measuring Symptom Distress in Cancer Patients

M.D. Anderson Cancer Center

NCT00505245

RECRUITING 2,000 participants

Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer

Jonsson Comprehensive Cancer Center

NCT02280161

RECRUITING 1,100 participants

Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer

Rutgers, The State University of New Jersey

NCT02688517

RECRUITING NA 1,001 participants

Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing

New Mexico Cancer Research Alliance

NCT06207864

RECRUITING NA 590 participants

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

M.D. Anderson Cancer Center

NCT01365169

RECRUITING 500 participants

Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers

University of Southern California

NCT03207854

RECRUITING Phase 1 440 participants

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Tyligand Pharmaceuticals (Suzhou) Limited

NCT06385925

RECRUITING Phase 1 270 participants

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

Merck Sharp & Dohme

NCT06818643

RECRUITING Phase 1 250 participants

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

Merck Sharp & Dohme

NCT07247110

RECRUITING Phase 2 250 participants

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

Merck Sharp & Dohme

NCT06979596

RECRUITING Phase 3 180 participants

Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases

M.D. Anderson Cancer Center

NCT03741673

RECRUITING NA 180 participants

Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials

University of Chicago

NCT05886764

RECRUITING Phase 1 168 participants

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

OncoResponse

NCT06090266

RECRUITING Phase 2 130 participants

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Merck Sharp & Dohme

NCT07252739

RECRUITING Phase 2 100 participants

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

M.D. Anderson Cancer Center

NCT02479698

RECRUITING Phase 2 100 participants

Intraoperative Tumor Margin Identification With ICG Dye Imaging

Massachusetts General Hospital

NCT04752137

RECRUITING NA 70 participants

Decreasing Chemotherapy Induced Distress Using Immersive Virtual Reality in Patients With Cancer

Case Comprehensive Cancer Center

NCT06446115

RECRUITING Phase 1 50 participants

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

Merck Sharp & Dohme

NCT06941272

RECRUITING NA 20 participants

A Study to See if an iPhone Weight Management App Can Help Promote Weight Loss in Adolescents and Young Adults After a Stem Cell Transplant

Jonsson Comprehensive Cancer Center

NCT04453072

ACTIVE NOT RECRUITING NA 434 participants

Reproductive Health Program in Patients With Cancer

ECOG-ACRIN Cancer Research Group

NCT01806129

ACTIVE NOT RECRUITING NA 325 participants

Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer

Alliance for Clinical Trials in Oncology

NCT03857620

ACTIVE NOT RECRUITING 170 participants

Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment

National Cancer Institute (NCI)

NCT02243592

ACTIVE NOT RECRUITING 160 participants

Novel Single Wave Assessment in Measuring Cardiac Dysfunction and Metabolic Syndrome in Patients With Cancer

City of Hope Medical Center

NCT04014231

ACTIVE NOT RECRUITING Phase 1 155 participants

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

NCT01552434

ACTIVE NOT RECRUITING Phase 2 135 participants

Dexamethasone in Controlling Dyspnea in Patients With Cancer

M.D. Anderson Cancer Center

NCT03367156

ACTIVE NOT RECRUITING 72 participants

Blood Samples to Identify Biomarkers in Patients Treated With Cyclophosphamide After Donor Stem Cell Transplant

City of Hope Medical Center

NCT04160390

ACTIVE NOT RECRUITING NA 56 participants

rTMS in Improving Neuropathy in Patients With Stage I-IV Cancer Who Have Received Oxaliplatin Chemotherapy

M.D. Anderson Cancer Center

NCT03219502

ACTIVE NOT RECRUITING NA 35 participants

Meditation Therapy in Improving Anxiety and Depression in Cancer Patients With Psychosocial Distress

M.D. Anderson Cancer Center

NCT02988271

ACTIVE NOT RECRUITING NA 28 participants

Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers

UNC Lineberger Comprehensive Cancer Center

NCT05823740

ACTIVE NOT RECRUITING Phase 1 24 participants

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases

City of Hope Medical Center

NCT03696030

ACTIVE NOT RECRUITING 10 participants

Web-Based Family Outreach Program for Cancer Prevention in High-Risk Families

M.D. Anderson Cancer Center

NCT02337452

ACTIVE NOT RECRUITING Phase 2 6 participants

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Jonsson Comprehensive Cancer Center

NCT01697527

COMPLETED NA 1,000 participants

Music in Reducing Distress in Participants with Cancer During Chemotherapy Treatment

Barbara Ann Karmanos Cancer Institute

NCT03683420

COMPLETED NA 746 participants

Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy in Reducing Insomnia in Cancer Survivors

University of Rochester NCORP Research Base

NCT02613364

COMPLETED Phase 3 690 participants

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Alliance for Clinical Trials in Oncology

NCT03578081

COMPLETED NA 418 participants

Multimedia Psychoeducation or Print Education in Preparing Cancer Patients for Decision Making About Clinical Trials

Gary Morrow

NCT02054715

COMPLETED NA 377 participants

Evidence-Based Tobacco Cessation Strategies in Patients With Cancer

Wake Forest University Health Sciences

NCT02211196

COMPLETED Phase 3 300 participants

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

Academic and Community Cancer Research United

NCT02585713

COMPLETED NA 125 participants

Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits

M.D. Anderson Cancer Center

NCT03856060

COMPLETED NA 124 participants

Music Therapy Video Development in Improving Communication, Emotional Distress, and Recovery in Adolescents/Young Adults Undergoing Treatment for High-Risk Cancer and Their Parents

Children's Oncology Group

NCT01556256

COMPLETED Phase 3 118 participants

Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant

Children's Oncology Group

NCT00305851

COMPLETED 115 participants

A Survey of Parent/Caregiver Practices on the Storage, Use, and Disposal of Opioids in a Comprehensive Cancer Center

M.D. Anderson Cancer Center

NCT03390283

COMPLETED NA 102 participants

Palliative Radiation Therapy in Reducing Pain in Patients With Bone Metastasis

Wake Forest University Health Sciences

NCT02699697

COMPLETED 100 participants

Communication Effectiveness in Cancer Treatment

Wake Forest University Health Sciences

NCT02197091

COMPLETED NA 91 participants

Tailoring Patient Education to Perceived Risk for Falls in Hospitalized Oncology Patients

Case Comprehensive Cancer Center

NCT02081794

COMPLETED Phase 2 87 participants

Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer

University of Rochester NCORP Research Base

NCT03186638

COMPLETED 82 participants

Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials

AIDS Malignancy Consortium

NCT01946217

COMPLETED Phase 1 63 participants

Evaluation of Food Effect on Pharmacokinetics of Vismodegib

National Cancer Institute (NCI)

NCT01174264

Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 10
Phase 2 8
Phase 3 4

Named interventions

Most-linked intervention names on Malignant Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Questionnaire Administration Other
19 trials
Quality-of-Life Assessment Other
10 trials
Laboratory Biomarker Analysis Other
8 trials
questionnaire administration Other
6 trials
Best Practice Other
4 trials
Interview Other
3 trials
laboratory biomarker analysis Other
3 trials
Cetuximab Biological
3 trials

US sites by state

Facility locations filed on Malignant Neoplasm trials. A trial with sites in several states counts in each.

Texas 20 trials
California 15 trials
Illinois 11 trials
North Carolina 8 trials
Florida 8 trials
New Jersey 7 trials
Minnesota 7 trials
Pennsylvania 6 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Malignant Neoplasm page

61 registered trials, 21 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malignant Neoplasm condition card totals 61 registered trials; most-linked intervention Questionnaire Administration; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.